Kathelijne C.J.M. Kraal

Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma

Michelle L. Tas, Ardine Reedijk, Henrike E. Karim‐Kos et al. · European Journal of Cancer · 2019 · 72 citations · Full text

Upfront treatment of high‐risk neuroblastoma with a combination of ¹³¹I‐MIBG and topotecan

Kathelijne C.J.M. Kraal, Godelieve A.M. Tytgat, Berthe L.F. van Eck‐Smit et al. · Pediatric Blood & Cancer · 2015 · 39 citations

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

Thomas Blom, Roosmarijn Lurvink, Leonie Aleven et al. · Frontiers in Oncology · 2021 · 32 citations · Full text

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells

Gerharda H. Boerman, Monique M. van Ostaijen-ten Dam, Kathelijne C.J.M. Kraal et al. · Cancer Immunology Immunotherapy · 2015 · 30 citations · Full text

Il-15-activated Nk Cells, Cell Therapy, Cancer Immunosurveillance +15

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Michelle L. Tas, Michelle Nagtegaal, Kathelijne C.J.M. Kraal et al. · Pediatric Blood & Cancer · 2019 · 30 citations · Full text